Can Combining Different Risk Interventions into a Single Formulation Contribute to Improved Cardiovascular Disease Risk Reduction? Rationale and Design for an International, Open-Label Program to Assess the Effectiveness of a Single Pill (Amlodipine/Atorvastatin) to Attain Recommended Target Levels for Blood Pressure and Lipids (The Jewel Program)